7390

543434

SUPRIYA

img img img img
No Data Available

SUPRIYA LIFESCIENCE LTD Share Price Update

As of the latest trading session, SUPRIYA LIFESCIENCE LTD is trading at ₹774.1, up by ₹40.19 or 5.47% from its previous close. The stock has moved between ₹731.35 and ₹794.00 today. Over the past year, the stock has delivered a return of 6.69%. In the last month, it has returned 18.00%.

SUPRIYA LIFESCIENCE LTD performance

Today’s low Today’s high
₹ 731.35 ₹ 794.00
₹ 774.10
52 week low 52 week high
₹ 545.50 ₹ 832.40
₹ 774.10
Open Price ₹ 739.90
Prev. Close ₹ 733.90
Volume (Shares) 1046228.00
Total traded value ₹ 8098.85
Upper Circuit ₹ 880.65
Lower Circuit ₹ 587.15
info

Investment Returns

Over 1 Month 18.00% Over 3 Months 15.64% Over 6 Months 3.78% Over 1 Year 6.69%
demotext Smart Investing Starts here ! Trade Smart with Fast Execution & Zero Account Opening Fees Invest Now

SUPRIYA LIFESCIENCE LTD fundamentals


  • Market cap (Cr) 6,230.20
  • P/E Ratio (TTM) 33.64
  • Beta 1.14
  • Book Value / share 134.41
  • Return on equity 20.74%
  • EPS (TTM) 23.06
  • Dividend yield 0.13%
  • Net profit/quarter (Cr) 49.68
info icon alternate text
  • Market cap (Cr) 6,232.20
  • P/E Ratio (TTM) 33.64
  • Beta 1.00
  • Book Value / share 134.41
  • Return on equity 20.74%
  • EPS (TTM) 23.06
  • Dividend yield 0.13%
  • Net profit/quarter (Cr) 49.68
info icon alternate text

SUPRIYA LIFESCIENCE LTD Financials

  • Key Results
  • Key Ratios
  • Balance sheet
  • Cash Flow
  • Competition
info-icon
Revenue
Net income
Particulars DEC 2025 (Values in Cr)
Revenue 206.44
Operating Expense 141.67
Net Profit 49.68
Net Profit Margin (%) 24.06
Earnings Per Share (EPS) 6.17
EBITDA 74.22
Effective Tax Rate (%) 25.77
Particulars SEP 2025 (Values in Cr)
Revenue 199.83
Operating Expense 134.25
Net Profit 50.43
Net Profit Margin (%) 25.23
Earnings Per Share (EPS) 6.27
EBITDA 75.38
Effective Tax Rate (%) 26.18
Particulars JUN 2025 (Values in Cr)
Revenue 145.07
Operating Expense 100.33
Net Profit 34.79
Net Profit Margin (%) 23.98
Earnings Per Share (EPS) 4.32
EBITDA 54.37
Effective Tax Rate (%) 26.61
Particulars MAR 2025 (Values in Cr)
Revenue 184.11
Operating Expense 123.03
Net Profit 50.38
Net Profit Margin (%) 27.36
Earnings Per Share (EPS) 6.29
EBITDA 70.56
Effective Tax Rate (%) 21.35
Particulars DEC 2024 (Values in Cr)
Revenue 185.65
Operating Expense 125.17
Net Profit 46.78
Net Profit Margin (%) 25.19
Earnings Per Share (EPS) 5.82
EBITDA 68.05
Effective Tax Rate (%) 25.24
Particulars MAR 2025 (Values in Cr)
Revenue 696.49
Operating Expense 457.82
Net Profit 187.96
Net Profit Margin (%) 26.98
Earnings Per Share (EPS) 23.35
EBITDA 270.61
Effective Tax Rate (%) 24.35
Particulars MAR 2024 (Values in Cr)
Revenue 570.37
Operating Expense 415.32
Net Profit 119.11
Net Profit Margin (%) 20.88
Earnings Per Share (EPS) 14.80
EBITDA 183.61
Effective Tax Rate (%) 28.11
Particulars MAR 2023 (Values in Cr)
Revenue 460.94
Operating Expense 346.94
Net Profit 89.86
Net Profit Margin (%) 19.49
Earnings Per Share (EPS) 11.16
EBITDA 138.39
Effective Tax Rate (%) 27.23
Particulars MAR 2022 (Values in Cr)
Revenue 530.05
Operating Expense 330.38
Net Profit 151.81
Net Profit Margin (%) 28.64
Earnings Per Share (EPS) 18.86
EBITDA 221.57
Effective Tax Rate (%) 26.75
Particulars MAR 2021 (Values in Cr)
Revenue 391.25
Operating Expense 228.91
Net Profit 123.59
Net Profit Margin (%) 31.58
Earnings Per Share (EPS) 16.89
EBITDA 178.15
Effective Tax Rate (%) 26.13
Particulars MAR 2025 (Values in Cr)
Book Value / Share 123.84
ROE % 20.74
ROCE % 27.43
Total Debt to Total Equity 0.01
EBITDA Margin 34.62
Particulars MAR 2024 (Values in Cr)
Book Value / Share 101.31
ROE % 15.73
ROCE % 22.05
Total Debt to Total Equity 0.02
EBITDA Margin 28.85
Particulars MAR 2023 (Values in Cr)
Book Value / Share 86.91
ROE % 13.67
ROCE % 18.43
Total Debt to Total Equity 0.04
EBITDA Margin 26.79
Particulars MAR 2022 (Values in Cr)
Book Value / Share 76.50
ROE % 34.34
ROCE % 41.97
Total Debt to Total Equity 0.11
EBITDA Margin 37.65
Particulars MAR 2021 (Values in Cr)
Book Value / Share 36.70
ROE % 59.18
ROCE % 55.75
Total Debt to Total Equity 0.37
EBITDA Margin 41.34
Particulars MAR 2025 (Values in Cr)
Cash & Short Term Investments 79.15
Total Assets 1112.31
Total Liabilities 1112.31
Total Equity 996.76
Share Outstanding 8
Price to Book Ratio 5.92
Return on Assets (%) 16.89
Return on Capital (%) 18.86
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 74.95
Total Assets 921.44
Total Liabilities 921.44
Total Equity 815.36
Share Outstanding 8
Price to Book Ratio 3.27
Return on Assets (%) 12.92
Return on Capital (%) 14.61
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 157.58
Total Assets 820.27
Total Liabilities 820.27
Total Equity 699.45
Share Outstanding 8
Price to Book Ratio 2.19
Return on Assets (%) 10.95
Return on Capital (%) 12.55
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 227.90
Total Assets 734.76
Total Liabilities 734.76
Total Equity 615.68
Share Outstanding 8
Price to Book Ratio 6.44
Return on Assets (%) 20.66
Return on Capital (%) 23.83
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 89.27
Total Assets 445.46
Total Liabilities 445.46
Total Equity 268.58
Share Outstanding 7
Price to Book Ratio 0.00
Return on Assets (%) 27.74
Return on Capital (%) 36.49
Particulars MAR 2025 (Values in Cr)
Net Income 248.48
Cash from Operations 223.85
Cash from Investing -152.24
Cash from Financing -8.23
Net change in Cash 4.19
Free Cash Flow 386.23
Particulars MAR 2024 (Values in Cr)
Net Income 165.69
Cash from Operations 150.95
Cash from Investing -173.57
Cash from Financing -22.35
Net change in Cash -82.62
Free Cash Flow 296.60
Particulars MAR 2023 (Values in Cr)
Net Income 123.48
Cash from Operations 94.28
Cash from Investing -123.65
Cash from Financing -10.27
Net change in Cash -70.32
Free Cash Flow 202.19
Particulars MAR 2022 (Values in Cr)
Net Income 207.24
Cash from Operations 109.76
Cash from Investing -59.82
Cash from Financing 149.65
Net change in Cash 138.63
Free Cash Flow 169.66
Particulars MAR 2021 (Values in Cr)
Net Income 167.30
Cash from Operations 105.88
Cash from Investing -46.80
Cash from Financing -14.51
Net change in Cash 14.57
Free Cash Flow 154.12
Company Name Price P/E P/B Market Cap 52 Week Low 52 Week High
AMBALAL SARABHAI ENT L 33.07 13.67 1.60 253.43 23.12 40.00
BLISS GVS PHARMA LTD. 300.20 24.29 2.66 3175.78 118.35 304.30
CIPLA LTD 1398.95 27.70 3.28 113007.26 1165.55 1672.20
FERMENTA BIOTECH LTD. 302.65 10.07 2.27 890.73 256.40 399.00
GLAXOSMITHKLINE PHARMA LT 2309.80 38.33 17.25 39129.41 2218.00 3515.95
Company Name Price P/E P/B Market Cap 52 Week Low 52 Week High
AMBALAL SARABHAI ENT L 33.07 23.13 4.26 253.43 23.12 40.00
AMRUTAJAN HEALTH LTD 558.20 25.02 4.35 1613.79 490.00 789.95
ASTRAZENECA PHARMA INDIA LTD. 8604.25 103.40 26.92 21510.63 7630.00 10653.05
BLISS GVS PHARMA LTD. 300.20 32.28 2.74 3175.78 118.35 304.30

SUPRIYA LIFESCIENCE LTD shareholding pattern

Holding
20.84%
68.29%
5.15%
5.7%
Name Shares Category
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)

News

Left Arrow
Right Arrow

SUPRIYA LIFESCIENCE LTD Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
774.10 5.47 redarrow
red-green-graph indicator
0 Bearish
16 Bullish
  • 5 Days 735.20
  • 26 Days 690.40
  • 10 Days 718.30
  • 50 Days 673.80
  • 12 Days 713.80
  • 100 Days 675.00
  • 20 Days 698.90
  • 200 Days 678.80
732.42 PIVOT
First Support 722.48 First Resistance 743.83 Second Support 711.07 Second Resistance 753.77 Third Support 701.13 Third Resistance 765.18
RSI 73.15 ADX 42.61 MACD 23.39 Williams % R -15.55 Commodity Channel Index (CCI) 267.79
Date 2026-05-22 Week 125592.00 Same Day 288474.00 Month 112414.00
1 Year 1.15 3 Year 1.23
Over 1 Month
18.00% down
Over 1 Year
6.69% down
Over 3 Months
15.64% down
Over 3 Years
47.63% down
Over 6 Months
3.78% down
Over 5 Years
14.64% down

SUPRIYA LIFESCIENCE LTD Corporate Actions

Dividend date Dividend amount Dividend type Record date Instrument type
04 Sep 2025 1.0 Final 05 Sep 2025 Equity shares
20 Sep 2024 0.8 Final 21 Sep 2024 Equity shares
15 Sep 2023 0.6 Final 15 Sep 2023 Equity shares
01 Sep 2022 0.6 Final 02 Sep 2022 Equity shares
Dividend date Dividend amount Dividend type Record date Instrument type
04 Sep 2025 1.0 Final 05 Sep 2025 Equity shares
20 Sep 2024 0.8 Final 21 Sep 2024 Equity shares
15 Sep 2023 0.6 Final 15 Sep 2023 Equity shares
01 Sep 2022 0.6 Final 02 Sep 2022 Equity shares

Top Gainers

Top Losers

SUPRIYA LIFESCIENCE LTD Share Price

Supriya Lifescience Limited was initially constituted on October 29, 1985, as a 'Partnership Firm under the name M/s Supriya Chemicals'. The Partnership Firm was last re-constituted pursuant to a Partnership Deed dated November 30, 2007. Upon the conversion of M/s Supriya Chemicals' the Partnership Firm into a Public Limited Company, the Company got incorporated as Supriya Lifescience Limited' vide certified on March 26, 2008 by the Registrar of Companies, Mumbai.

The Company commenced operations in April, 2008. It is engaged in manufacturing and export of active pharmaceutical ingredients (APIs). The company is one of the key Indian manufacturers and suppliers of active pharmaceuticals ingredients,with a focus on research and development. The company have niche product offerings of 39 APIs focused on diverse therapeutic segments such as antihistamine, analgesic, anaesthetic, vitamin, anti-asthmatic and antiallergic. The company have consistently been the largest exporter of Chlorpheniramine Maleate and Ketamine Hydrochloride from India, contributing to 45-55% and 65-70%, respectively,of the API exports from India, between Fiscal 2017 and 2020.

The company is among the largest exporters of Salbutamol Sulphate from India in Fiscal 2020 in terms of volume.The company's products are approved by various international regulatory authorities such as USFDA, EUGMP, EDQM, SFDA NMPA, ANVISA, KFDA, PMDA, TGA and Taiwan FDA. As of 31 March 2021, the company have filed 11 active DMFs with USFDA and seven active CEPs with EDQM, for API products in therapeutic areas such as antihistamine, analgesic, anaesthetic, vitamin, anti-asthmatic and anti-allergic.

The company's business operations are supported by a modern manufacturing facility located in Parshuram Lote, Maharashtra. The manufacturing facility is spread across 23,806 sq.mts, having reactor capacity of 332 KL per day.The company presently operate five cleanrooms and are setting up two new clean rooms that are expected to be commercialised in the first quarter of Fiscal 2022.

In December 2021, the Company came up with an Initial Public Offer aggregating to Rs 700 crore out of which Rs 500 crore was Offer for Sale (OFS) and Rs 200 was Fresh Issue.

In 2022-23, the Company acquired a manufacturing facility with the objective of commissioning backward integration projects. The Company initiated the construction of a new warehouse and administration block, which comprises a new quality control and assurance lab. It acquired plot of land at Isambe near Patalganga for capacity expansion.

In 2025, the Company commissioned state-of-the-art Module E production block at Lote Parshuram, increasing the installed capacity
from 597 KLPD to 932 KLPD.

Parent organization Indian Private
NSE symbol SUPRIYA
Founded 2008
stock
Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Right Arrow

Similar stocks

Left Arrow
Right Arrow

Frequently Asked Questions

What is the Current Share Price of Supriya Lifescience Ltd?

Answer Field

Supriya Lifescience Ltd share price is for NSE ₹ 774.10 & for BSE ₹ 774.35 as on May 22 2026 03:30 PM.

What is the Market Cap of Supriya Lifescience Ltd Share?

Answer Field

The market cap of Supriya Lifescience Ltd for NSE ₹ 6,230.20 & for BSE ₹ 0.00 as on May 22 2026 03:30 PM.

What is the 52 Week High and Low of Supriya Lifescience Ltd?

Answer Field

The 52 Week High and Low of Supriya Lifescience Ltd for NSE is ₹ 832.40 and ₹ 545.50 and for BSE is ₹ 831.00 and ₹ 545.65.

What is 1 year return for Supriya Lifescience Ltd?

Answer Field

The 1 year returns on the stock has been 6.69%.

What is the P/E Ratio of Supriya Lifescience Ltd Share?

Answer Field

As on May 22 2026 03:30 PM the price-to-earnings (PE) ratio for Supriya Lifescience Ltd share is 33.64.

What is the PB ratio of Supriya Lifescience Ltd Share?

Answer Field

As on May 22 2026 03:30 PM, the price-to-book (PB) ratio for Supriya Lifescience Ltd share is 134.41.

How to Buy Supriya Lifescience Ltd Share?

Answer Field

You can trade in Supriya Lifescience Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Supriya Lifescience Ltd Share on Bajaj Broking App?

Answer Field

To buy Supriya Lifescience Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Supriya Lifescience Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

close-image

Get Free Demat Account*

+91
close-img

Authorise with OTP

Enter the 4-Digit OTP sent to
edit
OTP expires in 00:59
banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|